News und Analysen
Premier and 34 Leading Health Systems Partner with DeRoyal to Expand Domestic Production of Isolation Gowns
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, and 34 member health systems partnered with DeRoyal Industries Inc., a global medical manufacturer, to create a new joint
Prüfungsausschuss beschließt Erstattung medizinischer Leistungen für Behandlung mit Tumor-Therapie-Feldern in Deutschland
Wie Novocure (NASDAQ: NVCR) heute mitteilte, haben Vertreter der Bundesärztekammer und der Bundesvereinigung der gesetzlichen Krankenkassen die Erstattung ärztlicher Leistungen bei Indikation
Agilent Receives Expanded FDA Approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer
Agilent Technologies Inc. (NYSE: A) today announced it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer (TNBC)
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency
Regulatory News:
Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results
EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and advances Joint Pharmaceutical Technology Development
Vancouver, B.C., November 13, 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
EnWave unterzeichnet Anlagenkaufvertrag mit GEA Lyophil GmbH und treibt gemeinsame Entwicklung der pharmazeutischen Technologie voran
Vancouver, B.C., 13. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab
Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the
IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the
Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the
Relay Medical & Fio meldet Verträge im Wert von über $500.000 CAD für Fionet Mobile COVID-19 Test- und Nachverfolgungsplattform und stellt operatives Update zur Verfügung
- Relay & Fio Joint Venture, Fio Rapid Response Group, kündigen über $500.000 CAD in ersten Verträgen an
- Fionet ist die erste mobile Test- und Nachverfolgungsplattform
Relay Medical & Fio Announces Over $500,000 CAD in Contracts for Fionet Mobile COVID-19 Testing & Tracking Platform; Provides Operational Update
- Relay & Fio joint venture, Fio Rapid Response Group, announce over $500,000 CAD in initial contracts
- Fionet is a first-of-its-kind mobile testing & tracking platform
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit
. Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1
Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
NanoString to Present at the Stifel 2020 Virtual Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the company’s management is scheduled to present
Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg
Pfizer Inc. (NYSE: PFE) announced today the publication of an analysis showing that VYNDAQEL® (tafamidis meglumine) 80 mg/VYNDAMAX® (tafamidis) 61 mg were associated with a statistically
For First Time, Humana Offering Medicare Advantage Health Plans in Massachusetts
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding the health plan choices for people eligible for Medicare in Massachusetts by offering Humana Medicare Advantage health
Humana Delivers COVID-19 Relief and Recovery Assistance to Community Service Organizations in Ohio
As the coronavirus pandemic continues to present health care and financial challenges to Ohio communities, leading health and well-being company Humana Inc. (NYSE: HUM) and its philanthropic
EnWave Signs First Commercial Royalty-Bearing License for Cannabis Processing in the United States
Vancouver, B.C., November 12 , 2020
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced
EnWave unterzeichnet erste kommerzielle Lizenz zur Zahlung von Lizenzgebührenür die Verarbeitung von Cannabis in den Vereinigten Staaten
Vancouver, B.C., 12. November 2020
Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
Dexcom Announces Upcoming Virtual Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:
-
Steve Pacelli, Executive Vice President
Charles River and PathoQuest Strengthen Strategic Partnership
PathoQuest SAS, a genomic expert company dedicated to quality control testing of biologics, and its strategic partner Charles River Laboratories International, Inc. (NYSE: CRL), announced today
PerkinElmer SARS-CoV-2 RT-PCR Assay Receives CE Mark for Saliva and Sample Pooling to Test Symptomatic and Asymptomatic Individuals
PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer® SARS-CoV-2 Real-time RT-PCR Assay received CE-IVD marking for the use of saliva as specimen type and the option to pool up to five